PhRMA’s 2018 Special 301 Submission targets Australia, Canada, S. Korea, Japan & others over pricing, reimbursement policies

In its 2018 Special 301 submission, PhRMA targets a number of countries for pricing and reimbursement policies deemed hostile to the pharmaceutical industry. Among these, PhRMA strategically lobbies for the strongest classifications for Canada and Korea — countries dealing with… Continue Reading

Negotiations on R&D funding agreements

1994 1994: Pharmaceutical Drugs, Intellectual Property Rights and Public Health: A Consumer Perspective from the United States, May 12. A discussion of how R&D mandates can ensure innovation does not suffer when prices lowering policies are embraced. 1996 1996: Comments… Continue Reading

Copyright and Related Rights

We have a lot of information on copyright issues,some reported in the blogs about trade negotiations like TPP, ACTA and NAFTA, RCEP or the WIPO SCCR negotiations. In addition to having separate pages on several of the trade negotiations, we… Continue Reading

Compulsory licensing

Global norms on compulsory licensing Country experiences Compulsory licensing in the United States Statutory authority for compulsory licenses on patents in the United States Compulsory licensing as a remedy to anticompetitive practices Compulsory licensing under the Bayh-Dole Act Compulsory licensing… Continue Reading

SCCR 25

November 19 to November 23, 2012 WIPO’s Page for the Meeting WIPO Copyright Committee (SCCR 25) begins week of negotiations. Treaties for disabilities and broadcasting are focus Intervention of African Group at WIPO copyright committee (SCCR25) Obama v blind people,… Continue Reading

Knowledge Governance Fora

KEI follows a number of negotiations over global norms for knowledge governance. Among the multilateral fora where KEI has been particularly active are the Geneva based World Intellectual Property Organization (WIPO), the World Trade Organization (WTO) and the World Health… Continue Reading